Candalb Supplement – Natural Formula to a Promote Healthy Intestinal Flora
Candalb provides natural ingredients with several benefits, which act synergistically to encourage a healthy balance of intestinal and vaginal flora.
Why supplement with Candalb?
Candida albicans is a yeast which is naturally present in the body, particularly in intestinal and genital mucous membranes. In certain circumstances, Candida albicans can become pathogenic and cause infections ranging from superficial to systemic mycoses.
Candida albicans is actually responsible for over 70% of the vaginal infections which affect most women at least once in their lifetime. An imbalance in intestinal and vaginal flora can encourage the pathogenic potential of the body's natural bacteria. A number of factors can lead to such an imbalance, particularly the use of antibiotics or an upset to the immune system. You can now buy Candalb at Supersmart to help fight these infections, as well as improving intestinal and vaginal health.
What are the benefits of the ingredients in Candalb capsules?
- Probiotics, such as and , combined with inulin which promote balanced intestinal and vaginal microflora, prevent the development of potentially pathogenic bacteria and stimulate the immune system, as well as boosting the efficacy of antibiotics.
- Caprylic acid is a medium-chain fatty acid (MCT) and a common treatment for the control of Candida albicans. It is naturally present in coconuts. Its sodium salt, sodium caprylate, breaks down the cell walls of the yeast, preventing it from spreading, and restoring ‘friendly' gut flora. Sodium caprylate is very well tolerated by the digestive system.
- Arabinogalactan, extracted from Western larch (Larix occidentalis) is a safe and effective anti-fungal, used widely to treat candida and vaginal mycosis. In addition, its efficacy in supporting the immune system by stimulating the proliferation of lymphokines is scientifically supported. It is a powerful weapon against persistent or recurrent infections.
- , a proteolytic enzyme, which helps reduce toxins in the intestine and reactions to foreign bodies. It also boosts antibiotic efficacy.
Buy Candalb capsules and promote a balanced microflora.
|Daily serving: 2 capsules
Number of servings per bottle: 30
Lactobacillus acidophilus La-5
||5,4 MD CFU
Arabinogalactan (extracted from Larix occidentalis)
Bifidobacterium lactis 33 %, Lactobacillus rhamnosus 33 %,,
Lactobacillus plantarum 33 %
|5 MD CFU
Serratia peptidase (gastroresistant fine granules)
of Serratia peptidase 2000 units/mg)
Other ingredients : acacia gum.
Directions for use
Adults : take two capsules in a single dose with a main meal, every day for a month. Repeat as necessary.
Once opened, keep refrigerated.
No reviews for this product yet
- Sardi, J. C. O., Scorzoni, L., Bernardi, T., Fusco-Almeida, A. M., and Mendes Giannini, M. J. S. (2013) Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol 62: 10–24
- Manzoni, P., Mostert, M., Leonessa, M. L., Priolo, C., Farina, D., Monetti, C., et al. (2006) Oral Supplementation with Lactobacillus casei Subspecies rhamnosus Prevents Enteric Colonization by Candida Species in Preterm Neonates: A Randomized Study. Clin Infect Dis 42: 1735–1742.
- Brunke, S., and Hube, B. (2013) Two unlike cousins: Candida albicans and C. glabrata infection strategies. Cell Microbiol 15: 701–708.
- Foxman, B., Muraglia, R., Dietz, J.-P., Sobel, J. D., and Wagner, J. (2013) Prevalence of Recurrent Vulvovaginal Candidiasis in 5 European Countries and the United States. J Low Genit Tract Dis 17: 340–345.
- Underwood JA, Williams JW, Keate RF. Clinical findings and risk factors for Candida esophagitis in outpatients. Dis Esophagus 2003;16:66-9.
- Hofs, S., Mogavero, S., and Hube, B. (2016) Interaction of € Candida albicans with host cells: virulence factors, host defense, escape strategies, and the microbiota. J Microbiol 54: 149–169.
- Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol. 2001; 183:5385–5394.
- Baehr PH, McDonald GB. Esophageal infections : Risk factors, presentation, diagnosis, and treatment. Gastroenterology 1994;106:509-32.
- Ghosh S, Navarathna DHMLP, Roberts DD, Cooper JT, Atkin AL, Petro TM, et al. Arginineinduced germ tube formation in Candida albicans is essential for escape from murine macrophage line RAW 264.7. Infect Immun. 2009; 77:1596–1605.
- Rodnei Dennis Rossoni et al, Junqueira (2018) Antifungal activity of clinical Lactobacillus strains against Candida albicans biofilms: identification of potential probiotic candidates to prevent oral candidiasis, Biofouling, 34:2, 212-225, DOI: 10.1080/08927014.2018.1425402
- Parolin, C., Marangoni, A., Laghi, L., Foschi, C., Nahui Palo- ~ mino, R. A., Calonghi, N., et al. (2015) Isolation of Vaginal Lactobacilli and Characterization of Anti-Candida Activity. PLoS ONE 10: e0131220
- Marten B, Pfeuffer M, Schrezenmeir J: Medium-chain triglycerides. Int Dairy J 2006;16:1374–1382.
- Ashwini Jadhav et al. The Dietary Food Components Capric Acid and Caprylic Acid Inhibit Virulence Factors in Candida albicans Through Multitargeting, JOURNAL OF MEDICINAL FOOD J Med Food 00 (0) 2017, 1–8 # Mary Ann Liebert, Inc., and Korean Society of Food Science and Nutrition DOI: 10.1089/jmf.2017.3971
- Takahashi M, Inoue S, Hayama K, Ninomiya K, Abe S: Inhibition of Candida mycelia growth by a medium chain fatty acids, capric acid in vitro and its therapeutic efficacy in murine oral candidiasis. Med Mycol J 2012;53:255–261.
- Bergsson G, Arnfinnsson J, Steingrı´msson O´ , Thormar H: In vitro killing of Candida albicans by fatty acids and monoglycerides. Antimicrob Agents Chemother 2001;45:3209–3212.
- Shivani Bhagat, MonikaAgarwal, Vandana Roy. Serratiopeptidase: A systematic review of the existing evidence, International Journal of Surgery, Volume 11, Issue 3, April 2013, Pages 209-217, https://doi.org/10.1016/j.ijsu.2013.01.010
- Prebiotic capacity of inulin-type fructans. Kolida S, Gibson GR. J Nutr. 2007 Nov;137(11 Suppl):2503S-2506S. Review.
- Bartholomew GA, Rodu B, Bell DS. Oral candidiasis in patients with diabetes mellitus : A thorough analysis. Diabetes Care 1987;10:607-12.
- Yakoob J, Jafri W, Abid S, et al. Candida esophagitis : Risk factors in non-HIV population in Pakistan. World J Gastroenterol 2003;9:2328-31.
- Mimidis K, Papadopoulos V, Margaritis V, et al. Predisposing factors and clinical symptoms in HIV-negative patients with Candida oesophagitis : Are they always present ? Int J Clin Pract 2005;59:210-3
- Weerasuriya N, Snape J. A study of Candida esophagitis in elderly patients attending a district general hospital in the UK. Dis Esophagus 2006;19:189-92